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ABSTRACT
Objective To investigate the comparative effectiveness 
of all treatments for patellofemoral pain (PFP).
Design Living systematic review with network meta- 
analysis (NMA).
Data sources Sensitive search in seven databases, 
three grey literature resources and four trial registers.
Eligibility criteria Randomised controlled trials 
evaluating any treatment for PFP with outcomes ’any 
improvement’, and pain intensity.
Data extraction Two reviewers independently 
extracted data and assessed risk of bias with Risk of 
Bias Tool V.2. We used Grading of Recommendations, 
Assessment, Development and Evaluation to appraise the 
strength of the evidence.
Primary outcome measure ’Any improvement’ 
measured with a Global Rating of Change Scale.
Results Twenty- two trials (with forty- eight treatment 
arms) were included, of which approximately 10 (45%) 
were at high risk of bias for the primary outcome. Most 
comparisons had a low to very low strength of the 
evidence. All treatments were better than wait and see 
for any improvement at 3 months (education (OR 9.6, 
95% credible interval (CrI): 2.2 to 48.8); exercise (OR 
13.0, 95% CrI: 2.4 to 83.5); education+orthosis (OR 
16.5, 95% CrI: 4.9 to 65.8); education+exercise+patellar 
taping/mobilisations (OR 25.2, 95% CrI: 5.7 to 
130.3) and education+exercise+patellar taping/
mobilisations+orthosis (OR 38.8, 95% CrI: 7.3 
to 236.9)). Education+exercise+patellar taping/
mobilisations, with (OR 4.0, 95% CrI: 1.5 to 11.8) or 
without orthosis (OR 2.6, 95% CrI: 1.7 to 4.2), were 
superior to education alone. At 12 months, education or 
education+any combination yielded similar improvement 
rates.
Summary/conclusion Education combined with a 
physical treatment (exercise, orthoses or patellar taping/
mobilisation) is most likely to be effective at 3 months. At 
12 months, education appears comparable to education 
with a physical treatment. There was insufficient evidence 
to recommend a specific type of physical treatment over 
another. All treatments in our NMA were superior to wait 
and see at 3 months, and we recommend avoiding a 
wait- and- see approach.
PROSPERO registeration number PROSPERO 
registration CRD42018079502.
INTRODUCTION
Musculoskeletal disorders are one of the largest 
global contributors to years lived with disability, and 
costly to society.1 Patellofemoral Pain (PFP) is one 
of the most common knee complaints in individuals 
between 10 and 50 years of age.2 PFP impacts func-
tion, ability to participate in leisure time activities, 
work, sport and reduces quality of life.3 It is a clin-
ical diagnosis made when patients present with pain 
around or behind the patella during daily activities 
such as stair walking, squatting or running. Similar 
to low back pain, PFP is characterised by a high 
degree of persistency and recurrence of symptoms. 
Nearly 40% of those with PFP continue to expe-
rience symptoms after 2 years, which is associated 
with frequent use of pain killers, lowering of phys-
ical activity levels and low quality of life.4 5
Many different treatments are used in clinical 
practice to help patients with PFP.6 While there 
are several systematic reviews evaluating treat-
ments for PFP,7–9 the comparative effectiveness of 
all available treatments has never been examined. 
This makes deciding on the most appropriate treat-
ment challenging and may explain the variation 
in clinical practice.6 In this study, we use network 
meta- analysis (NMA), a technique which allows the 
simultaneous comparison of multiple interventions 
in a single coherent analysis. Traditional systematic 
review quickly become outdated.10 Living system-
atic reviews are continuously updated and incor-
porate new evidence when available.11 A living 
systemic review with NMA would enable clinicians 
to consult a contemporary, comprehensive over-
view of the comparative effectiveness of treatments 
for a given condition. This living systematic review 
with NMA evaluates the comparative effectiveness 
of all available treatments for patients with PFP, 
providing a comprehensive and up- to- date over-
view of evidence- based treatments.
METHODS
Protocol registration
The living systematic review with NMA was 
prospectively registered on PROSPERO and a full 
protocol was published.12 The findings are reported 
in accordance with the Preferred Reporting Items 
for Systematic Reviews and Meta- Analyses checklist 
extension for NMA.13
Deviations from protocol
Deviations from the protocol relate to including 
a minimum number per treatment arm (>10) (to 
avoid resource intensive review work for very little 
gain), exclusion of adverse effects as an outcome 
(due to a lack of available data) and removal of 
threshold analyses (due to substantial overlap in 
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credible intervals (CrIs)). Deviations are outlined in more detail 
in online supplemental appendix 1.
Administration, dissemination and updating the living 
systematic review
This review will be administered at the Center for General 
Practice at Aalborg University, Denmark, and we plan to 
update the NMA annually for a minimum of 5 years. As 
described in our protocol, we will screen the literature annu-
ally to identify new data that may alter our conclusions and 
recommendations. When new data have become available, we 
will update the analysis and present the updated findings at 
the website of Aalborg University (https://www. almenmedicin. 
aau. dk/ forskning/ forskningsomraade1/). Here, we will also 
provide a plain- language summary for patients and clinicians 
dealing with PFP.
Patient and public involvement
Seven patients with PFP formed a patient reference group to 
select the hierarchy of outcomes (Global Rating of Change 
(GROC) Scale and pain scales). One researcher not involved in 
the study (acknowledgements) explained the various outcomes 
and participants indicated what they considered the most rele-
vant instrument. Six of the seven indicated a preference for the 
GROC Scale. Consequently, the outcomes were prioritised as 
follows:
Primary outcome measure
Any improvement on a GROC Scale, a commonly used outcome 
with excellent reliability, intraclass correlation coefficients 
(ICCs) range from 0.90 to 0.99.14 15 Any improvement is defined 
as any15 degree of recovery or improvement. ‘Unchanged’ to 
‘worse than ever’ are considered a treatment failure.
Secondary outcome measures
Pain intensity measured by ‘worst pain in the past week’ on a 
Visual Analogue Scale (VAS; 0–10/0–100) or Numerical Rating 
Pain Scale (NRS; 0–10/0–100). The reliability is excellent, 
ICC=0.76.15 16
Patient- rated pain during specific activities of daily life and 
during sporting activities measured16 on a VAS or NRS as 
outlined above. Reliability for pain during activity is excellent, 
ICC=0.83.
Patient- reported outcome measures were not included as they 
have not been used for PFP until very recently.17 These may be 
included in future updates.
Research question
Based on the main purpose of the study and the input from our 
patient reference group, we formulated the following research 
question: Which treatment(s)/treatment category (class(es)) is 




Published or unpublished randomised controlled trials (RCTs) 
(including randomisation through minimisation, or clustering) 
were eligible for inclusion providing a full- text report was 
available.
Type of population
All patients with a clinical diagnosis of PFP were included. 
Studies were included if they used synonyms for PFP, but as 
minimum criterion, described patients with retropatellar or peri-
patellar pain, of at least 6- week duration, and a non- traumatic 
onset. The diagnostic criteria used in the original studies were 
followed, given that pain was described as being retropatellar 
or peripatellar pain. Studies examining other conditions were 
excluded (eg, patellar dislocations, patellofemoral osteoar-
throsis, patellar tendinopathy, Osgood- Schlatter, iliotibial band 
syndrome, Sinding- Larsen- Johansson syndrome). Trials that 
included participants diagnosed with PFP, but with concomitant 
pain around the patella caused by other conditions (eg, patellar 
tendinopathy), were eligible for inclusion. No age restrictions 
were imposed.
Type of treatments and control treatments
Any conservative or invasive treatment, control treatment, 
placebo, wait- and- see or no treatment group studied were 
eligible for inclusion.
Type of outcomes
Studies assessing the treatment effect after a minimum of 6 weeks 
were included. Studies assessing the primary and secondary 
outcomes above were included (GROC Scale, worst pain inten-
sity during the previous week and pain during activities).
Search strategy
We developed a sensitive search strategy which included a mix of 
indexed and free- text terms (see Winters et al12). No restrictions 
(eg, language or full- text availability) were applied. We searched 
conventional databases, grey literature databases and trial 
registers. The following sources were searched from their date 
of inception up till 4 June 2019: Embase, PubMed (including 
MEDLINE), Cochrane Central Register of Controlled Trials, 
Scopus, Web of Science, CINAHL, SPORTDiscus.  OpenGrey. 
eu and  WorldCat. org were searched for unpublished studies and 
conference proceedings were identified from all Patellofemoral 
Research Retreats (2009, 2011, 2013, 2015 and 2017). For 
unpublished or ongoing studies, we searched the WHO Inter-
national Clinical Trials Registry Platform (http:// apps. who. int/ 
trialsearch/) Clinical  Trials. gov, The European Union Clinical 
Trials Register and the ISRCTN registry. Finally, we screened 
reference lists of all Cochrane reviews (N=6) on PFP and the 
reports included in this review for possible relevant studies that 
were not identified by our search.
Study selection
Two researchers (MW and CBL) screened titles and abstracts 
independently after duplicate removal. Consensus was sought in 
cases of initial disagreement. If consensus could not be reached, 
the report was included for full- text evaluation. Both investiga-
tors independently applied our inclusion and exclusion criteria 
to the full- text reports. In case of disagreement, consensus was 
sought; however, if disagreement persisted a third author (MSR 
or AW) arbitrated the decision.
We used Covidence (Melbourne, Australia) for independent 
study selection, data extraction and risk of bias assessment.
Data extraction
Data were extracted by two researchers using standardised 
extraction forms adapted from the Cochrane Collaboration.18 
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Any disagreements were resolved by consensus. We extracted the 
following data:
 ► Publication and study details: For example, authors, year of 
publication, funding source, possible conflicts of interest, 
study aim, design and unit of allocation.
 ► Population: Number of patients included, population char-
acteristics for age, sex, body mass index, activity level, 
setting where population was recruited, baseline scores for 
outcome measures (mean, SDs, standard errors extracted for 
continuous outcomes and number and percentage for cate-
gorical outcomes).
 ► Eligibility criteria and diagnostic criteria used for PFP.
 ► Treatments: For example, number randomised to group, 
detailed description of for example, application, dose, 
intensity, frequency, number of sessions, delivery, tailoring 
(individual/group), duration of treatment, providers, cotreat-
ments, modification (change to treatment), adherence. We 
used items from the Template for Intervention Description 
and Replication checklist12 19 to assure comprehensive data 
extraction in this section of the extraction form.17
 ► Outcomes: Timepoints measured, and the timepoints 
reported on, outcome definition, person measuring, unit of 
measurement, scales (upper and lower limits), imputation of 
missing data, primary and secondary outcomes used in the 
original trials, unintentional outcomes (eg, adverse events, 
adverse effects, side effects).
 ► Data and analysis: Comparisons, outcomes, subgroups, time-
points, results (central estimates and measures of dispersion; 
eg, mean for both groups, mean difference (MD), SDs/95 
CIs/standard errors), number of missing patients, statistical 
methods used and appropriateness of these.
 ► Other information: Key conclusions of study authors.
Risk of bias assessment
The Cochrane Risk of Bias Tool V.2 was used to assess the risk 
of bias for each outcome per study. We assessed bias following 
the ‘intention- to- treat’ principle (ie, assignment to interven-
tion).20 This tool has a fixed set of items to use for the risk of bias 
appraisal, that is, ‘bias arising from the randomisation process’, 
‘bias due to deviations from intended interventions’, ‘bias due to 
missing outcome data’, ‘bias in measurement of the outcome’, 
‘bias in selection of the reported result’ and overall risk of bias 
judgement for each outcome.
Pairs of two (MW and CBL; MW and AW) independently 
assessed all RCTs included. Each major domain of bias was 
appraised in light of each included study outcome. The tool’s 
signalling questions and criteria were followed to inform a 
domain- based appraisal of the risk of bias. The risk of distor-
tion of the outcome estimate was appraised as at ‘low’, ‘some’ 
or ‘high’ risk of bias. We made judgements regarding the direc-
tion of distortion ‘favours experimental’, ‘favours comparator’, 
‘towards null’, ‘away from null’ or ‘unpredictable’. Each outcome 
within a study received an overall risk of bias judgement based 
on the individual domains; ‘low’, ‘some’ or ‘high’ risk of bias, 
following the guidance from the tool. In case of disagreements 
between reviewers, consensus was reached through discussions 
in all cases.
Data synthesis and statistical methods
We constructed network plots using Stata software (StataCorp. 
V.2017. Stata Statistical Software:118 Release 15. College 
Station, Texas: StataCorp LLC) to visualise all head- to- head 
comparisons for all outcomes.21 Networks of treatment compar-
isons were constructed for the primary and secondary outcome 
separately. Three authors (MW, SH, MSR) appraised the clinical 
homogeneity before the start of the analysis, by tabulating study 
and population characteristics and inspecting them for differ-
ences in potential effect modifiers. This informed assessment 
of the assumption of exchangeability required for NMA. Treat-
ments were also assigned to categories (ie, classes) (table 1).
Our primary outcome measure, any improvement, was 
summarised using an OR for improvement versus non- 
improvement, with a 95% CrI. This was in line with our 
protocol, and done because various GROC Scales, with different 
number of response options and descriptors (eg, improvement vs 
recovery), did not allow for data to be analysed in a proportional 
odds regression model. We used a conservative intention- to- treat 
approach to the analyses where missing data in original studies 
was handled as a treatment failure.
For our secondary outcome measures, worst pain and pain 
descending stairs intervention effects were expressed as MDs, 
with 95% CrIs, when outcomes were measured with the same 
instrument. Pain measured on a 0–100 scale was converted to 
0–10 where necessary. Mean and median ranks and 95% cred-
ibility limits were used to estimate the likelihood of individual 
Table 1 Treatments and treatment categories (ie, classes) for the ‘any improvement’
Categories (ie, classes) Category definition Treatments Studies
Education Education consisted of information/advice given by a healthcare 
practitioner on patellofemoral pain, (aggravating) activity/exercise and 
management of pain/symptoms. Delivered either face to face or in the 
form of written materials
Education Rathleff et al,27 Linschoten et 
al,25 Collins et al26
Education+exercise therapy+patellar 
taping/mobilisations
Education (as above), combined with resistance exercise (as described 
below) and application of taping/movement to the patella
Education+exercise therapy+patellar 
taping/mobilisations
Rathleff et al,27 Linschoten et 
al,25 Collins et al26
Education+orthosis Education (as above) in combination with prefabricated orthotics to be 
placed under the foot in the shoe to support the arch




A combination of these treatments outlined above/below Education+exercise therapy+patellar 
treatments+orthosis
Collins et al26
Wait and see No treatment or continuing with current/planned management Wait and see Mills et al,44 Drew et al32
Exercise therapy Resistance exercise, that is, muscles contracting against resistance 
provided in the form of weights, bands or body/limb weight with the 
goal of improving muscle strength, endurance or mass. Programmes 
targeted the lower limb and/or trunk muscles (with/without general 
aerobic conditioning as warm- up/cooldown). This could be delivered 
face to face or as a home exercise programme
Exercise hip/knee Matthews et al,43 Baldon et 
al,30 Giles et al,39 Riel et al,48 
Drew et al32
Exercise hip/knee trunk Baldon et al30
Exercise hip/knee+blood flow restriction Giles et al39
Exercise hip/knee with feedback Riel et al48
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treatments being superior to the other treatments for the indi-
vidual with PFP.
NMA models were fitted for both treatment categories (ie, 
classes’; overarching treatment categories outlined in table 1), 
and individual treatments. For all analyses, we fitted fixed 
and random effects NMA models22 at the treatment level, and 
compared model fit using the deviance information criterion 
and posterior mean residual deviance (lower measures of both 
statistics are preferred, with differences of 3 or more consid-
ered meaningful). In accordance with our protocol, we grouped 
outcome follow- ups based on the available data, that is, 3 and 
12 months. If there were multiple timepoints available for an 
outcome, and these were equally close to the timepoint to be 
synthesised across studies, the last follow- up in this timeframe 
was used. For the class- level models, we fitted hierarchical (ie, 
random) and fixed effect between treatment within- class models 
and compared model fit as described above. For the secondary 
outcome measures worst pain and pain descending stairs, we 
also attempted to fit bivariate models to capture the correlation 
in treatment effects on these related outcomes.
If >10 studies were available per comparison, we assessed 
statistical heterogeneity by inspecting the between- study SD, 
and by comparing fit of the fixed and random effect models. 
We assessed the consistency assumption for each network by 
comparing model fit between the NMA model and an unrelated 
mean effects model that relaxes the consistency assumption.23 
We assessed small study bias using comparison- adjusted funnel 
plots if 10 or more trials were available for 1 comparison.24 We 
ran a sensitivity analysis to test if our findings were robust for 
our decision to pool the study arms (education vs education+ex-
ercise) in van Linschoten et al25 with the study arms in Collins 
et al26 and Rathleff et al27 (both education vs education+exer-
cise+patellar treatments).
NMA models were fitted in a Bayesian framework using 
Markov chain Monte Carlo simulations in WinBUGS (V.1.4, 
Medical Research Council, UK, and Imperial College of Science, 
Technology and Medicine, University of Cambridge, UK). A 
Bayesian analysis estimates a posterior distribution which we 
summarise with the mean or median, and 95% CrIs. 95% CrIs 
are interpreted as a range of values within which a parameter 
lies with a 95% chance. CrIs are very similar to CIs in frequen-
tist analyses but may be wider for random effects models due 
to Bayesian analyses incorporating uncertainty around the 
between- studies SD.
Certainty of the evidence (Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE) approach)
After the analysis, we used the GRADE approach to assess the 
certainty of the evidence from the NMA.28 29 Two researchers 
graded (MW and AW, see acknowledgements) the evidence on 
the basis of the risk of bias assessments, inconsistency, indirect-
ness, imprecision and publication bias. We assigned an overall 
judgement about the certainty of the evidence for all compari-
sons, and for the evidence from the NMA as a whole.
RESULTS
Selection process
We included 22 RCTs. figure 1 details the search and selection 
process. Online supplemental appendix 2 shows the studies 
excluded+the reasons for exclusion. Thirty- three trials were 
found through register searches; sixteen were completed, nine 
were ongoing and eight trials’ status was unknown (online 
supplemental appendices 3 and 4).
Characteristics of the studies included
Twenty- one treatments were investigated in twenty- two 
trials.25–27 30–48 Forty- eight treatment arms were investigated, 
with sample sizes from 10 to 109 per treatment arm. Thirty- six 
(75%) of arms included exercise. Other common intervention 
categories included patient education, orthotics and wait and see 
(or a combination). For full details see table 1 and online supple-
mental appendix 5. Eleven RCTs used a GROC Scale to measure 
patient- reported outcomes, and nineteen trials used a worst pain 
scale or measured pain during a specific activity. Cumulatively, 
1472 patients with PFP were included. Online supplemental 
appendix 5 details all study and patient characteristics of the 
studies included.
Risk of bias and certainty of the evidence
The majority of outcomes were at high risk of bias (79%), with 
some concerns in 21% (online supplemental appendix 6, tables 1 
and 2a,b). Outcome measurement (45%), deviations from the 
intended intervention (45%), missing outcome data (32%) and 
reporting (23%) were the most common sources of bias.
The certainty of evidence for all comparisons was low to very 
low, except for hip/knee exercises versus education+orthosis, 
for which there was moderate evidence (online supplemental 
appendix 7). Evidence for comparisons was rated down for risk 
of bias (n=100, 100%; ie, ‘serious’ to ‘very serious’) and impre-
cision (n=85, 85%).
NETWORK META-ANALYSES
Figure 2 shows direct treatment comparisons in the field of PFP 
for any improvement. Nine studies could be included in the 
NMA at 3 months, and three studies in the NMA at 12 months. 
Six classes were included in network analyses for the primary 
outcome (table 1). Model fit statistics are reported in online 
supplemental appendix 8. On the basis of model fit, we report 
results for the fixed effect model with random between treat-
ment within class effects for any improvement at 3 months. We 
report results for a fixed effect treatment model without class for 
any improvement at 12 months, as it was not possible to conduct 
class- level analyses for any outcomes at 12 months, or for pain 
while descending stairs at 3 months, as only single treatments 
were available. Estimated individual treatment effects for ‘any 
improvement’, ‘worst pain’ and ‘pain while descending stairs’ 
are presented in online supplemental appendix 9. No other 
measures for pain during an activity could be synthesised in an 
NMA. None of the networks showed evidence of inconsistency 
between direct and indirect comparisons, where data from direct 
and indirect evidence were available. Too few trials were avail-
able to investigate heterogeneity, or small study bias. Six studies 
that could not be included in an NMA are presented in a descrip-
tive synthesis in online supplemental appendix 10; among the 
six there were two studies that could have been connected to the 
network if data were available.
Online supplemental appendix 11 provides the findings for 
the sensitivity analysis. It shows that our main findings are robust 
for our decision to pool the education+exercise arm in van 
Linschoten et al25 with the education+exercise+patellar treat-
ments arms in Collins et al26 and Rathleff et al.27
Comparative treatment (class) effectiveness on the primary 
outcome (‘any improvement’)
Any improvement at 3 months
The fixed effect model with hierarchical (ie, random) effect 
between treatments within the class showed that all treatment 
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classes were superior to wait and see: education (OR 9.6, 95% 
CrI 2.2 to 48.8), exercise (OR 13.0, 95% CrI: 2.4 to 83.5), educa-
tion+orthosis (16.5, 95% CrI: 4.9 to 65.8), education+exer-
cise+patellar taping/mobilisations (25.2, 95% CrI: 5.7 to 130.3) 
and education+exercise+patellar taping/mobilisations+orthosis 
(38.8, 95% CrI: 7.3 to 236.9) (table 2a).
Education+exercise+patellar taping/mobilisations, with or 
without orthosis, was superior to education alone (2.6, 95% CrI: 
1.7 to 4.2, and, 4.0, 95% CrI: 1.5 to 11.8, respectively). Neither 
exercise (prescribed on its own) nor orthosis+education was 
superior to education alone (1.3, 95% CrI: 0.3 to 6.3, and, 1.7, 
95% CrI: 0.8 to 4.0, respectively). No specific type of exercise 
was superior to another type of exercise (online supplemental 
appendix 9).
Any improvement at 12 months
At 12 months, four treatment arms were compared in a fixed 
effects treatment model. No differences were found for educa-
tion+exercise+patellar taping/mobilisations (OR 1.5, 95% CrI: 
0.9 to 2.4), education+orthosis (2.3, 95% CrI: 1.0 to 6.2) or 
education+exercise+patellar taping/mobilisations+orthosis 
(1.9, 95% CrI: 0.8 to 4.9) when compared with education alone 
(table 2b).
Treatment (class) rankings ‘any improvement’
Education+exercise+patellar taping/mobilisations, either with 
or without orthosis, was the best combination of treatments for 
PFP at 3 months (median ranking 1, median’s 95% CrI: 1 to 3; 
Figure 1 Flow diagram, search on 4 June 2019. PFP, patellofemoral pain; RCTs, randomised controlled trials.
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and, median ranking 2, 95% CrI: 1 to 4, respectively). Wait and 
see was least likely to be effective (median ranking 6, 95% CrI: 
6 to 6) (table 3).
At 12 months, education+exercise+patellar taping/mobilisa-
tions, either with (median ranking 2, 95% CrI: 1 to 4) or without 
(median ranking 3, 95% CrI: 1 to 4) orthosis, and education+or-
thosis (median ranking 1, 95% CrI: 1 to 4) showed similar rank-
ings. Education alone seemed least likely to be effective (median 
ranking 4, 95% CrI: 3 to 4).
Comparative treatment effectiveness on the secondary 
outcomes
Comparative treatment effects for worst pain at 3 months, as 
estimated by random effects model with random between treat-
ments within class effect, are reported in online supplemental 
appendix. We report on the results from a fixed effects model 
without class effect for worst pain at 12 months. The pooled 
findings for ‘worst pain’ at 3 months show that none of the treat-
ments was found to be superior to any other treatment or to wait 
Figure 2 Network graphs for direct treatment comparisons for any improvement at 3 months (A) and 12 months (B). Blue text represents the 
number of treatment comparisons, and the text in black represents the number of participant that received the respective treatment. The thickness 
of the lines and the size of the dots are proportional to the number of trial comparisons and the number of participants in the treatment arms, 
respectively.
Table 2a Treatment effects for the primary outcome: Comparative treatment class effects for any improvement at 3 months (fixed effects model 







































ORs with their 95% credible intervals from the network meta- analysis are shown.
For any cell, an OR<1 favours the upper- left treatment, and an OR>1 favours the lower- right treatment. Comparative treatment effect differences are shown in bold.




















ORs with their 95% credible intervals (CrIs) from the network meta- analysis are shown in the lower left triangle, and ORs with their 95% CrIs from the pairwise meta- analyses 
(ie, direct evidence from randomised controlled trials) in the upper- right triangle. For any cell, an OR<1 favours the upper- left treatment, and an OR>1 favours the lower- right 
treatment.
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and see. At 12 months, education+exercise+patellar taping/
mobilisations appears superior to education alone. Educa-
tion+exercise+patellar taping/mobilisations+orthosis appears 
better than education alone but was not found to be superior to 
education+exercise+patellar taping/mobilisations.
For pain while descending stairs, three treatments could 
be compared. All analyses were performed using fixed effects 
models without class effects. At 3 months, an exercise programme 
including hip, knee and trunk exercises was superior to hip and 
knee exercises alone and to a programme including ‘minimal’ 
hip/knee exercises. No difference was found between minimal 
hip/knee exercises and usual hip/knee exercises. At 12 months, 
hip, knee and trunk exercises were superior to a combination 
of hip/knee exercises and arthroscopy, and also superior to hip/
knee exercises alone. No difference was found between hip/knee 
exercises+arthroscopy or hip/knee exercises alone.
DISCUSSION
This living systematic review included 22 RCTs with a total of 
1472 patients with PFP for more than 6 weeks. All treatments 
were superior to a wait- and- see approach for the primary 
outcome, any improvement, at 3 months. Patient education 
combined with a physical treatment appears most effective in 
the short term. After 12 months, education or education+ad-
ditional exercises, orthosis or patellar treatment yielded similar 
improvement rates. However, no studies included wait and see 
for any improvement at 12 months precluding comparisons to 
determine if this was also inferior in the longer term. For the 
secondary outcome, pain intensity during previous week, no 
treatment was superior to wait and see.
Guidelines for musculoskeletal pain often recommend a 
wait- and- see approach in general practice.49 Based on this 
NMA, wait and see is the least effective treatment available. 
Clinicians should, therefore, avoid a wait- and- see approach. 
Clinicians can consider a minimum of patient education at 
the first consultation and potentially add exercise and patellar 
taping/mobilisations if the patient and clinician agree on the 
time requirements and benefit. Costs may be another aspect to 
consider when offering add- on treatments. If additional treat-
ments such as exercise and patellar taping/mobilisations have 
limited persisting benefit in the long term, these treatments 
may not represent value for money. Trials should include cost 
evaluations in the future.
One of the studies not included in NMA demonstrated 
that among runners, patient education on load management 
may be equally as effective as patient education and exercise 
therapy or patient education and gait retraining. These find-
ings are in contrast to the findings from the NMA that suggest 
education may be inferior to education+physical treatments 
at 3 months. Future trials may need to explore which types of 
education may be most effective, and how it can be improved 
even further as a low cost and scalable intervention. Education 
varied in terms of how it was delivered. Education in all trials 
included information about PFP, information on pain and 
guidance on how to manage activity in the context of pain, 
without stopping all exercise. This also has important implica-
tions for research, as many studies include some educational 
material as a control, with few available studies using a true 
control or placebo control. The ‘wait- and- see’ arms often also 
included patients continuing with their planned treatments 
and therefore may not reflect a true no treatment control. 
Despite all treatments being superior to wait and see for any 
improvement, there was no superior effect of active treatments 
compared with wait and see on pain intensity.
If a resistance exercise programme is chosen, the specific 
type of exercises prescribed may not be important. They 
mainly comprise strengthening exercises for the hip, the knee 
or both the hip and knee. This gives clinicians the opportunity 
to devise an individual prescription together with their patient. 
The additional benefit of adding patellar taping/mobilisations 
to an exercise programme is presently unknown. Shared deci-
sion making between the patient and their healthcare practi-
tioner should guide administering the addition of a physical 
treatment to education. It appears that foot orthoses do not 
have an additive effect to education and exercise so clinicians 
should consider this when selecting adjuncts to education and 
exercise. On the other hand, orthosis and education combined 
had a similar effect as the combination of exercise, education 
and patellar treatments. This highlights two different treat-
ment approaches with different time requirement, which 
appear equally effective.
Strengths and weaknesses in relation to previous studies
Previous systematic reviews and RCTs on the management of 
PFP were restricted to traditional comparisons of one treat-
ment versus another, for example, patient education versus 
exercise. Similar to a Cochrane review,7 we found exercise to 
be superior to wait and see on any improvement, but not on 
pain. However, our NMA further suggests that combing exer-
cise, (with or without foot orthoses) to education may be most 
effective for 3- month improvements. This is in keeping with a 
recent consensus statement from experts in the field of PFP that 
recommends exercise, orthosis, manual therapy and combined 
treatments in the management of PFP.50 Our quantitative NMA 
supports the view that combined treatment is associated with 
the best outcomes, but that orthoses may not improve outcomes 
when added to education, exercises and patellar taping/mobil-
isations. Our living NMA will be updated when new evidence 
becomes available, ensuring a contemporary overview of the 
evidence for the best treatment of PFP for patients and clinicians 
dealing with the condition.
Strengths and weaknesses of this study
There was an overall lack of high- quality, large studies, with only 
one study including>100 subjects per trial arm.43 Small trials 
with varying quality predominate in the field of musculoskel-
etal health. To ensure, we included credible research to inform 
the NMA we only included research where (1) patients had 
the condition for ≥6 weeks, and (2) studies included relevant 
Table 3 Treatment rankings from the network meta- analyses for any 
improvement.
Treatment (class)











1.36 1 (1 to 3) 2.03 2 (1 to 4)
Education+exercise+patellar 
taping/mobilisations
2.12 2 (1 to 4) 2.56 3 (1 to 4)
Education+orthosis 3.17 3 (2 to 5) 1.57 1 (1 to 4)
Exercise 3.77 4 (1 to 5) NA NA
Education 4.58 5 (3 to 5) 3.84 4 (3 to 4)
Wait and see 5.99 6 (6 to 6) NA NA
*Results from a fixed effects model with random between treatment within class effect.
†Results from a fixed effects model without class effect.
95% CrI, 95% credible interval; NA, not applicable.
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patient- rated outcomes and follow- ups (≥6 weeks). As a result, 
we excluded 128 RCTs. While the comparisons in those studies 
could add value to the body of knowledge, these were not eval-
uated by the patient—which is considered the gold standard of 
outcome measurement by WHO, and ‘essential’ by Cochrane.51 52 
Consensus on which outcomes to use in RCTs through the devel-
opment of a core outcome set has the potential to move the field 
of PFP forward. In our study, patients were involved in priori-
tising our outcomes making our results relevant to patients and 
clinical practice. We performed a comprehensive search covering 
published and unpublished studies, state- of- the- art risk of bias 
and GRADE assessments. We synthesised evidence in Bayesian 
hierarchical NMAs to optimally use all evidence to determine 
which treatment is best for PFP.
Limitations in the conclusions drawn by the NMA are 
primarily caused by the original data. Overall evidence was 
graded as very low to low. There was no evidence of heteroge-
neity between studies with fixed effect models preferred over 
random effects models based on model fit; however, this may 
be due to the limited number of studies available per compar-
ison. Consistency between direct and indirect evidence could 
not be checked for all comparisons in the NMAs. However, 
where this was possible, by comparing consistency models to 
models that relaxed the consistency assumption, we did not 
find evidence of inconsistency. Treatment outcomes may be 
different on the basis of some characteristics (ie, effect modi-
fication). Lankhorst et al53 suggested that sex and symptom 
duration may be effect modifiers in the relationship between 
exercise and function at 3 months, but no significant associa-
tion was found. As there is no good evidence for any potential 
effect modifier, we did not include potential effect modifiers 
when planning the synthesis. This is a limitation that can be 
overcome in the future when new evidence for effect modifiers 
becomes available. Studies should break down their results on 
the basis of potential effect modifiers, such as sex and dura-
tion of symptoms, which would allow exploring modification 
effects in the future.
Treatments provided for PFP, as with any musculoskeletal 
condition, are diverse. For example, the mode of delivery, 
frequency and intensity may be different for various exer-
cise regimes that we pooled together. This is a limitation; 
when more studies are done the effect of delivery, frequency 
and intensity of exercise could be formerly tested. We did 
subgroup exercise regimes per exercise region (eg, hip/knee 
or hip/knee/trunk exercises). The NMA suggests that it may 
not matter in which region exercises are performed. We ran 
a sensitivity analysis to test if our findings were robust for 
our decision to pool the study arms (education vs educa-
tion+exercise) in van Linschoten et al25 with the study 
arms in Collins et al26 and Rathleff et al27 (both education 
vs education+exercise+patellar treatments). The sensitivity 
analysis showed that this decision did not affect the NMA’s 
comparative estimates, and second, that patellar treatments 
in addition to education+exercise appear not to be effective 
to education+exercises alone.
Publication bias could not be investigated due to a lack of 
studies.18 24 We found a number of trials in registries that may 
have remained unpublished but it is unclear if this was due to 
publication or small study bias. Collectively, bias and low study 
quality decrease the certainty of our findings. We chose a conser-
vative statistical approach with the NMA, handling missing data 
as a treatment failure. This may balance out inflated effects in 
the original studies, or could even underestimate the compara-
tive effects.
CONCLUSION
Education combined with a physical treatment (exercise, orthoses 
or patellar taping/mobilisation) is most likely to be effective. 
There was insufficient evidence to recommend a specific type 
of physical treatment, or a combination of physical treatments, 
over another. All treatments analysed in our NMA were superior 
to wait and see at 3 months, and we recommend avoiding a wait- 
and- see approach.
What is already known
 ► Patellofemoral is a persisting condition, four in every ten 
patients continue to have symptoms after 2 years. It is 
disabling and it impacts on quality of life.
 ► Many patients receive multiple treatments that impacts 
healthcare consumption.
 ► The comparative effectiveness of all available treatments is 
currently unknown.
What are the new findings
 ► Our living network meta- analysis (NMA) of randomised 
controlled trials suggests that education in combination with 
a physical treatment (exercise, orthoses or patellar taping/
mobilisation) is most likely to be effective at 3 months.
 ► At 12 months education alone is comparable to education 
combined with a physical treatment (exercises, orthoses or 
patellar taping/mobilisation).
 ► All treatments analysed in our NMA were superior to wait 
and see, a common first- line approach currently administered 
by general practitioners.
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